| 33.97 0 (0%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.72 | 1-year : | 46.39 |
| Resists | First : | 34 | Second : | 39.72 |
| Pivot price | 33.77  |
|||
| Supports | First : | 33.44 | Second : | 33.09 |
| MAs | MA(5) : | 33.96 |
MA(20) : | 33.69 |
| MA(100) : | 32.48 |
MA(250) : | 30.04 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 93.6 |
D(3) : | 95.5 |
| RSI | RSI(14): 71.2 | |||
| 52-week | High : | 34.38 | Low : | 23.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VIVO ] has closed below upper band by 17.8%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.02 - 34.19 | 34.19 - 34.33 |
| Low: | 33.57 - 33.75 | 33.75 - 33.9 |
| Close: | 33.7 - 33.99 | 33.99 - 34.23 |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Mon, 22 Apr 2024
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings? - Yahoo Movies UK
Mon, 22 Apr 2024
Meridian Bioscience: Fiscal 4Q Earnings Snapshot - Yahoo Movies UK
Thu, 18 Apr 2024
Did You Miss Meridian Bioscience's (NASDAQ:VIVO) Impressive 189% Share Price Gain? - Yahoo Movies UK
Sat, 30 Mar 2024
Will Meridian Bioscience (VIVO) Gain on Rising Earnings Estimates? - Yahoo Movies UK
Fri, 29 Jul 2022
FDA re-authorizes Meridian Bioscience's COVID-19 assay - Mass Device
Thu, 07 Jul 2022
Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 44 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 90.9 (%) |
| Shares Short | 4,240 (K) |
| Shares Short P.Month | 3,430 (K) |
| EPS | 1.61 |
| EPS Est Next Qtrly | 0.15 |
| EPS Est This Year | 0.67 |
| EPS Est Next Year | 0.67 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | 12.7 % |
| Operating Margin | 22.7 % |
| Return on Assets (ttm) | 10.3 % |
| Return on Equity (ttm) | 12.1 % |
| Qtrly Rev. Growth | -13.9 % |
| Gross Profit (p.s.) | 4.29 |
| Sales Per Share | 7.59 |
| EBITDA (p.s.) | 2.1 |
| Qtrly Earnings Growth | -13 % |
| Operating Cash Flow | 82 (M) |
| Levered Free Cash Flow | 86 (M) |
| PE Ratio | 21.09 |
| PEG Ratio | 2.5 |
| Price to Book value | 5.25 |
| Price to Sales | 4.47 |
| Price to Cash Flow | 18.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-02-13 |
| Ex-Dividend Date | 2019-01-31 |
|
|
|
|
|
|
|
|
|